Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
45.8
％Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)2025年4月1日〜2025年9月30日Non-consolidated (standalone)Japanese GAAPNet Sales7,821¥ millionYear on year +8.7%Progress 51.1%
Operating profit262¥ millionYear on year -45.8%Progress 30.8%
Ordinary income227¥ millionYear on year -48.1%Progress 28.4%
Net income attributable to owners of the parent165¥ millionYear on year -55.0%Progress 27.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥7.65
Financial position at period-end
Total assets27,502¥ million
of which net assets 13,176 ¥ millionEquity ratio 47.9%vs. prior year-end -0.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+702
Investment-817
Financials+365
Net change+250
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥1,224 million
Regional salesRegion Domestic / Current interim period ¥3,255 million / Prior-year period ¥3,681 million, Region Exports / Current interim period ¥4,565 million / Prior-year period ¥3,515 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥15,300 million (YoY +1.1%)
Operating profit¥850 million (YoY -30.1%)
Ordinary income¥800 million (YoY -29.8%)
Net income¥600 million (YoY -33.1%)
Annual Dividend Forecast¥9 → ¥10（+11.1%）
Factors Behind Changes in Business Performance
海外向けの医薬品関連製品や高分子材料などの販売が好調で売上高は増加したが、アミノ酸製造設備の償却負担増等により段階利益は減少した。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Breakdown of extraordinary income (loss)Extraordinary income None (total extraordinary income: —) / Extraordinary loss Loss on Disposal of Fixed Assets ¥28 million
Depreciation and amortization¥691 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not disclosed)
Issued Shares at Period-End21,974,000 Shares
Treasury Shares at Period-End359,175 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 2025年4月1日〜2025年9月30日 |
| Net Sales | ¥7,821 million (YoY +8.7%) |
| Operating profit | ¥262 million (YoY -45.8%) |
| Ordinary income | ¥227 million (YoY -48.1%) |
| Profit attributable to owners of the parent | ¥165 million (YoY -55.0%) |
| Net income per share | ¥7.65 |
| Equity ratio | End of the current fiscal period 47.9 / End of previous period 48.8 |
| Total assets | ¥27,502 million |
| Net assets | ¥13,176 million |
| Cash flows from operating activities | ¥702 million |
| Cash flows from investing activities | ¥-817 million |
| Cash flows from financing activities | ¥365 million |
| Cash and cash equivalents at end of period | ¥1,224 million |
| Full-year earnings forecast | Net Sales ¥15,300 million (YoY +1.1%) / Operating profit ¥850 million (YoY -30.1%) / Ordinary income ¥800 million (YoY -29.8%) / Net income ¥600 million (YoY -33.1%) |
| Annual Dividend Forecast | ¥9 → ¥10（+11.1%） |
| Regional sales | Region Domestic / Current interim period ¥3,255 million / Prior-year period ¥3,681 million, Region Exports / Current interim period ¥4,565 million / Prior-year period ¥3,515 million |
| Depreciation and amortization | ¥691 million |
| Breakdown of extraordinary income (loss) | Extraordinary income None (total extraordinary income: —) / Extraordinary loss Loss on Disposal of Fixed Assets ¥28 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 21,974,000 Shares |
| Treasury Shares at Period-End | 359,175 Shares |
| Factors Behind Changes in Business Performance | 海外向けの医薬品関連製品や高分子材料などの販売が好調で売上高は増加したが、アミノ酸製造設備の償却負担増等により段階利益は減少した。 |
Items this document does not state (10)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitOrders received and order backlogImpairment lossChanges in the scope of consolidationMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.海外向けの医薬品関連製品や高分子材料などの販売が好調だった一方、本年6月に竣工したアミノ酸製造設備の償却負担増等により利益が減少した。原材料・物流・エネルギーコストの高騰も収益を圧迫している。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.